Diaceutics Share Price (DXRX)

They appear to book revenues before the services are actually provided.

Impressive results, already flashed in January. But...outlook for 2026 was 25% revenue growth. 15% achieved in 1Q26 and now no repeat of that f/c?

.wealthoracle.co.uk/admin/featured-companies

Diaceutics delivered a strong FY2025 performance, with revenue rising 20% to £38.4m and constant currency growth of 24%, alongside a return to profitability. Adjusted EBITDA increased 80% to £7.6m, with margins improving to 20%, while the group reported a pre-tax profit of £0.3m versus a £1.9m loss in FY2024. The results highlight increasing operating leverage within the DXRX platform as the business scales. The quality of growth was also encouraging. Annual Recurring Revenue (ARR) increased 19% to £20.0m, while the order book rose 56% to a record £38.9m, giving materially improved revenue visibility into 2026. Order book visibility for the next twelve months increased 19% to £21.1m, supporting management’s confidence in continued growth. Commercial momentum remained strong despite a tougher biotech and pharma spending backdrop. The number of customer therapeutic brands increased 12% to 95, while Diaceutics continued to work with 18 of the top 20 global pharma companies. Importantly, two additional top-10 pharma customers expanded into enterprise-wide engagements, demonstrating deeper strategic integration of the DXRX platform across customer organisations rather ...

.wealthoracle.co.uk/admin/featured-companies

Things going well. Company must be delivering in plans and perhaps over delivering. Must be good news coming?

Big drop. No explanation. A thin market so it could just be more tax/probate/estate planning ... At any price. Almost worth a comment from company, though. Is anyone listening?